NKMAX Utilizes NK View Kit to Determine Early COVID-19 Infection Treatment Method

[Asia Economy Reporter Hyungsoo Park] NKMAX announced on the 15th that the NK View Kit can be used to determine the timing and method of treatment for Coronavirus Disease 2019 (COVID-19).

According to a research paper released last week by researchers at The University of Ottawa Hospital, who are using the NK View Kit, the initial immune response of COVID-19 patients is one of the important factors in judging treatment effectiveness. Measuring NK cell activity through the NK View Kit helps determine the timing and method of treatment for early-stage patients.

Research and treatment for COVID-19 patients have been focused on severe cases. There are currently no specific measures for early-stage or mild patients. The University of Ottawa Hospital researchers emphasized that relying solely on methods such as social distancing has limitations in responding to COVID-19 resurgence, and it is important to focus on activating the immune response during the early infection stage. They believe that measuring NK cell activity at the early stage of COVID-19 infection to predict the likelihood of progression to severe disease and deciding the timing and method of treatment will enable effective response.

Katia Betito, head of NKMAX Canada, which supported the research, said, “We hope that the innate immune activation measurement test using the NK View Kit can soon be used as a predictive tool for symptom infection and treatment outcomes in high-risk COVID-19 patients.”

Unlike existing COVID-19 diagnostic kits that only confirm infection status, the NK View Kit is a tool that can diagnose the level of immunity attacking the COVID-19 virus. The University of Ottawa Hospital in Canada is conducting clinical research using the NK View Kit to quickly determine the severity of COVID-19 patients, whether to treat, and the order of treatment.